Filing Analysis
Protara Therapeutics, Inc. announced its quarterly financial results for the period ending June 30, 2026. The filing serves as a formal notice of the release of earnings via an attached press release.
📋 Key Facts
- Reporting date: August 11, 2026
- Period covered: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Protara Therapeutics, Inc. announced the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026. His responsibilities will be absorbed by existing clinical and R&D leadership.
🚩 Red Flags
- Sudden departure of a key C-suite officer (CMO) in a clinical-stage biotech company can signal internal friction or uncertainty regarding clinical trial progress.
📋 Key Facts
- Leonardo Viana Nicacio, M.D., resigned as Chief Medical Officer on June 26, 2026.
- Reason for departure: To explore other opportunities.
- Carla Beckham, M.D. (Lead Medical Director and Head of Clinical Development) will assume his duties.
- Oversight of the transition remains under Jacqueline Zummo, Ph.D. (Chief Research & Development Officer).
Protara Therapeutics completed a public offering of common stock and announced the full exercise of an underwriters' option. The total gross proceeds from the combined offering are expected to be approximately $86.3 million.
🚩 Red Flags
- Significant equity dilution resulting from the issuance of over 14.9 million new shares.
📋 Key Facts
- Completed public offering of 13,043,479 shares at $5.75 per share on December 8, 2025.
- Underwriters exercised their option in full for an additional 1,956,521 shares on December 11, 2025.
- Total expected gross proceeds: approximately $86.3 million (before fees and expenses).
- Proceeds are earmarked for clinical development of TARA-002, other clinical programs, and working capital.
Protara Therapeutics, Inc. entered into an underwriting agreement to issue 13,043,479 shares of common stock at $5.75 per share. The offering aims to raise approximately $75 million in gross proceeds to fund clinical development and working capital.
🚩 Red Flags
- Significant dilution: The issuance of over 13 million new shares will result in substantial dilution for existing shareholders.
📋 Key Facts
- Offering size: 13,043,479 shares of common stock.
- Public offering price: $5.75 per share.
- Expected aggregate gross proceeds: Approximately $75 million (before fees).
- Underwriters: J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Piper Sandler & Co.
- Over-allotment option: Underwriters have a 30-day option to purchase up to an additional 1,956,521 shares.
- Lock-up period: 60 days for the company's officers and directors regarding their shares.
- Use of proceeds: Funding clinical development of TARA-002, other clinical programs, and general working capital.
Protara Therapeutics reported positive updated interim data from its Phase 2 ADVANCED-2 Trial of TARA-002 for NMIBC, demonstrating a 72% overall complete response (CR) rate. The company also provided updates on regulatory dialogues with the FDA regarding expanded trial designs.
🚩 Red Flags
- Clinical trial data is interim and subject to further updates/potential changes as the study progresses.
📋 Key Facts
- Phase 2 ADVANCED-2 Trial: Reported an overall Complete Response (CR) rate of 72% (21/29 patients).
- 6-month CR rate was 69% (18/26); 12-month CR rate was 50% (7/14).
- Among initial responders, 88% maintained response through 6 months and 100% through 12 months.
- Safety profile: Majority of treatment-related adverse events (TRAEs) were Grade 1 and transient; no Grade 3 or greater TRAEs reported.
- FDA feedback supports a registrational design for a controlled trial in BCG-Naïve patients using intravesical chemotherapy as a comparator.
- Data cutoff date: November 7, 2025.
Protara Therapeutics announced interim clinical data from its Phase 2 STARBORN-1 trial for TARA-002 in pediatric patients with Lymphatic Malformations (LMs). The results showed high efficacy rates and a favorable safety profile, with most adverse events being mild to moderate.
🚩 Red Flags
- One patient discontinued treatment due to a Grade 2 Adverse Event (fatigue).
📋 Key Facts
- Interim analysis based on 12 patients enrolled in the STARBORN-1 trial as of November 12, 2025.
- 83% (5/6) of macrocystic patients achieved a complete response; one patient achieved substantial response.
- 100% (8/8) of patients who completed the eight-week response assessment achieved clinical success.
- Clinical success defined as 90%-100% reduction in total LM volume (complete) or 60%-90% (substantial).
- Safety profile: No serious adverse events (SAEs) reported; most common AEs were swelling and fatigue.
- One patient discontinued treatment due to a Grade 2 AE of fatigue.
Protara Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Quarter ended September 30, 2025
- The company is listed on the Nasdaq Global Market under ticker TARA
- Financial results were issued via press release (Exhibit 99.1)
Protara Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 11, 2025
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders on June 11, 2025. The filing reports the results of shareholder votes regarding director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Three Class II directors elected: Luke Beshar, Roger Garceau, M.D., and Gregory Sargen, to serve until the 2028 Annual Meeting.
- Stockholders ratified Ernst and Young LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Advisory approval was granted for the compensation of Named Executive Officers (NEOs).
- Shareholders approved an amendment to the 2024 Equity Incentive Plan.
- As of April 16, 2025, there were 38,579,021 shares of common stock outstanding.
Protara Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing is an announcement of results of operations and financial condition via Exhibit 99.1.
Protara Therapeutics reported interim clinical data from its Phase 2 ADVANCED-2 trial for TARA-002 in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The data showed significant complete response rates, particularly in the BCG-Unresponsive cohort.
🚩 Red Flags
- Small sample sizes in the BCG-Unresponsive cohort (n=5) and evaluable subsets may limit statistical significance of long-term data.
📋 Key Facts
- Phase 2 ADVANCED-2 trial assessing intravesical TARA-002 for NMIBC patients with carcinoma in situ (CIS).
- BCG-Unresponsive Cohort: 100% complete response (CR) rate at any time; CR rates were 80% at 9 months and 67% at 12 months.
- BCG-Naïve Cohort: 76% overall CR rate; CR rates were 63% at 6 months and 43% at 12 months (based on limited evaluable patients).
- Safety profile reported as mostly Grade 1 and transient, with no Grade 3 or greater treatment-related adverse events (TRAEs) reported.
- No patients discontinued treatment due to TRAEs.
Protara Therapeutics, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Financial results for the quarter and year ended December 31, 2024 were announced on March 5, 2025.
- The company is listed on the Nasdaq Capital Market under ticker TARA.
- Results are provided via a press release attached as Exhibit 99.1.
Protara Therapeutics announced the partial exercise of an underwriters' option related to its December 2024 public offering. The company expects total gross proceeds from the full offering and this partial exercise to reach approximately $102.7 million.
🚩 Red Flags
- None identified in this specific filing; the offering appears to be a standard capital raise via an S-3 shelf registration.
📋 Key Facts
- Underwriters exercised a portion of their option on January 8, 2025, purchasing an additional 438,738 shares of common stock.
- The original offering (completed Dec 11, 2024) consisted of 13,690,000 shares of common stock and 2,325,372 pre-funded warrants.
- Offering price was $6.25 per share of common stock and $6.249 per pre-funded warrant.
- Total expected gross proceeds from the offering (including partial option exercise) is approximately $102.7 million before expenses.
- Net proceeds are earmarked for clinical development of TARA-002, other clinical programs, working capital, and general corporate purposes.
Protara Therapeutics, Inc. completed a significant public offering of common stock and pre-funded warrants on December 11, 2024. The offering aims to raise approximately $100 million in gross proceeds to fund clinical development programs.
🚩 Red Flags
- Significant dilution: The issuance of over 13.6 million new shares represents a substantial increase in total share count.
- Pre-funded warrants: These are often used to bypass certain regulatory or investor restrictions but can lead to future dilution upon exercise.
📋 Key Facts
- Total aggregate gross proceeds expected: approximately $100 million (before fees).
- Offered 13,690,000 shares of common stock at $6.25 per share.
- Offered 2,325,372 pre-funded warrants at a price of $6.249 per warrant (effectively $0.001 exercise price).
- Underwriters include TD Securities (USA) LLC, Cantor Fitzgerald & Co., and LifeSci Capital LLC.
- Includes a 30-day over-allotment option for underwriters to purchase up to 2,402,305 additional shares.
- Proceeds are earmarked for the clinical development of TARA-002, other clinical programs, and general working capital.
Protara Therapeutics released interim clinical data from its Phase 2 ADVANCED-2 trial for TARA-002 in patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The data shows high complete response (CR) rates and a favorable safety profile.
🚩 Red Flags
- Forward-looking statements include risks regarding the ability to obtain sufficient financing to fund strategic plans and commercialization efforts.
📋 Key Facts
- Interim data cutoff date: November 19, 2024.
- TARA-002 showed a 72% complete response (CR) rate at six months for the overall evaluable population (n=18).
- In the pivotal cohort (BCG-Unresponsive), the CR rate was 100% (4/4) at six months.
- In the proof-of-concept cohort (BCG-Naïve), the CR rate was 64% (9/14) at six months.
- Safety profile: No Grade 2 or greater treatment-related adverse events reported; no discontinuations due to adverse events.
- Company plans to report initial data from 12-month evaluable patients in mid-2025.
Protara Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024 via a press release. The filing is a standard earnings announcement under Item 2.02.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Announcement date: November 12, 2024
- The filing includes results of operations and financial condition as per Exhibit 99.1.
Protara Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing is a standard earnings release notification under Item 2.02.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Quarter ended June 30, 2024
- Company announced financial results via press release (Exhibit 99.1)
- Ticker: TARA; Exchange: Nasdaq Capital Market
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders on June 7, 2024. The filing reports the results of several shareholder votes, including director elections and the ratification of auditors.
📋 Key Facts
- Annual Meeting held on June 7, 2024.
- Three Class I directors elected: Jane Huang, M.D., Richard Levy, M.D., and Michael Solomon, Ph.D.
- Ernst and Young LLP ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Shareholders approved advisory compensation for named executive officers.
- Shareholders approved the adoption of the 2024 Equity Incentive Plan.
- Shareholders approved the adoption of the 2024 Employee Stock Purchase Plan.
Protara Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Financial results for the quarter ended March 31, 2024 were released on May 2, 2024.
- The report was signed by Patrick Fabbio, Chief Financial Officer.
- Results are provided in Exhibit 99.1 via a press release.
Protara Therapeutics announced a $45 million private placement of common stock and warrants to fund clinical trials and working capital. The company also reported positive three-month data from its TARA-002 clinical program for Non-Muscle Invasive Bladder Cancer (NMIBC).
🚩 Red Flags
- Significant dilution: Issuance of over 9 million new shares plus warrants for up to 10.8 million additional shares.
- Warrant overhang: The potential issuance of a large number of common shares via warrants could create significant selling pressure.
📋 Key Facts
- Private placement of 9,143,380 shares of common stock and 1,700,000 pre-funded warrants.
- Total expected gross proceeds: approximately $45 million.
- Share price: $4.15 per share/warrant; Pre-Funded Warrant price: $4.149.
- Common Warrants exercisable at $5.25 (a ~30% premium to the April 4, 2024 closing price).
- Use of proceeds includes funding clinical trials (ADVANCED-2 Phase 2), manufacturing, and commercialization.
- TARA-002 three-month complete response (CR) rate was 38% across 16 evaluable patients.
- Closing anticipated on April 10, 2024.
Protara Therapeutics, Inc. announced the resignation of its Chief Medical Officer, Jathin Bandari, M.D., effective April 11, 2024. Dr. Bandari will transition to a consulting role through July 11, 2024 as part of a separation agreement.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) during active clinical trial phases.
- Significant severance package including lump sum salary and accelerated vesting of equity.
📋 Key Facts
- Jathin Bandari, M.D. (CMO) is resigning effective April 11, 2024.
- Dr. Bandari will provide consulting services through July 11, 2024.
- Separation agreement includes 9 months of base salary paid in a lump sum and reimbursement of COBRA premiums for 9 months.
- The agreement includes pro rata vesting of 11,993 options and 5,886 restricted stock units (RSUs).
- Jacqueline Zummo, Ph.D., will oversee medical staff responsible for clinical trials in the interim.
- Dr. Bandari is receiving a $150,000 cash retention award paid earlier in 2024.
Protara Therapeutics, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Financial results for the quarter and year ended December 31, 2023 were announced on March 13, 2024.
- The announcement was made through a press release (Exhibit 99.1).
- The filing is pursuant to Item 2.02 of Form 8-K.